Trial
NCT00741715
Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Sanofi
Collaborators
—
Condition
Hypercholesterolemia
Intervention
AVE5530
Why stopped
AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-16